Table 1.
Patient characteristics
| Characteristics | Patients |
| Entered | n = 54 |
| Age median (years) (range) | 46 years (range 25 – 73 y) |
| Estrogen receptor/progesterone receptor positive | 23/15 |
| HERcepTest+++/FISH+ | 51/3 |
| primary metastatic disease | 12 (22.2%) |
| Metastatic sites median (range) | 3 (range 1–7 sites) |
| Lung | 22 |
| Liver | 29 |
| Bones | 30 |
| Lymph nodes | 22 |
| Soft tissue | 36 |
| Skin | 11 |
| Brain | 11 |
| Others | 3 |
| More than one metastatic site | 48 (88.8%) |
| Adjuvant chemotherapy | 31 (57.4%) |
| Adjuvant docetaxel | 13 |
| Adjuvant anthracyclines | 19 |
| Adjuvant endocrine therapy | 15 (27.7%) |
| Palliative endocrine therapy | 20 (37%) |
| 1st line combination | n = 54 pts |
| Vinorelbine | 35 |
| Capecitabine | 2 |
| Gemcitabine | 0 |
| Docetaxel | 12 |
| Platinum derivatives | 0 |
| Others | 5 |
| 2nd line combination | n = 54 pts |
| Vinorelbine | 15 |
| Capecitabine | 11 |
| Gemcitabine | 9 |
| Docetaxel | 11 |
| Platinum derivatives | 0 |
| Others | 8 |
| Beyond 2nd line combination | n = 60 therapies |
| Vinorelbine | 6 |
| Capecitabine | 14 |
| Gemcitabine | 14 |
| Docetaxel | 4 |
| Platinum derivatives | 11 |
| Others | 11 |